| Yorkshire
Retina Society Winter
Meeting |
The
last full day meeting hosted by the York
Team.
Meeting
program for the day was as follows:
9.00
Registration and Coffee
9.25
Welcome
note. Meeting Chair Richard Gale
Symposium:
New therapies for nAMD
Chair
Miss Nicola Topping
9.30
Is 16
weeks
dosing the new expectation in AMD?
Experience with emerging therapies. Dr David
Brown, Retinal Consultants of Texas.
David
Brown’s attendance has been
supported through Bayer sponsorship of the
YRS meeting. Bayer has had no input
to the content of Dr Brown’s presentation.
9.55
‘Anatomical
Endpoints with Dual Inhibition: How
important are they'? #
Dr
Dilsher Dhoot, California Retina
Consultant.
Roche
Products Limited has provided
financial support for this meeting but has
had no involvement in the agenda
other than this organised presentation.
This is a promotional session and will
include discussions about Roche products.
10.20
Discussion
Debate
1: addressing unmet needs in nAMD.
Chair:
Mrs Archana Airody
Time
for a co-ordinated screening
programme for nAMD in the UK
10.35
Yes.
Richard
Gale, York
10.45
No. Peter
Scanlon, Oxford
10.55
Discussion
Coffee
Debate
2: A virtual service should be the mainstay of managing patients with
AMD.
11.35
Yes. Louise
Downey, Hull
11.45
No Tariq
Aslam, Manchester
11.55
Discussion
12.05
Lecture: Automated detection of treatable
Macular Disease in the community; is it
coming soon Pearse
Keane, Moorfields Eye Hospital
12.25
Discussion
12:30
Lunch and Exhibition
Symposium:
Update in the Management of
Uveitis Chair:
Greg Heath
13.30
Assessing
Endpoints in Uveitis: measuring what
matters: Nick Beare
13.45
Discussion:
13.55
Emerging
therapies in Uveitis : treating what
matters: Nick
Beare
14.05
Discussion
Case
presentations: Contemporary AMD or
Uveitis Cases
Chair : Divya Venugopal
(7 min presentations, 3
min questions)
14.15
– Presentations
Debate
3:
Complement inhibition therapies for
Geographic Atrophy will be a paradigm
shift.
14.45
Yes, Ian
Pearce, Liverpool
14.55
No, James
Talks, Newcastle
15.05
Discussion
Coffee
Keynote
presentations Chair:
Richard Gale
15.45
Which Cell
and Gene therapies will be in clinical
practice within 5 years?
Dilsher
Dhoot, California Retina
Consultants
16.05
Managing side effects of emerging therapies
for AMD. David Brown
David
Brown’s attendance has been
supported through Bayer sponsorship of the
YRS meeting. Bayer has had no input
to the content of Dr Brown’s presentation.
16.25
Discussion
‘Ask the experts’.
16.45
Summary
and close.
Online
Registration is closed
Meeting Evaluation is now closed
For a copy of the attendance certificate please
email admin@yorkshireretinasociety.com
The YRS is now a membership Society and there are
reduced registration fees to attend its
meetings. If you would like to support the
YRS and join the Society, please refer to the membership
section for more information
|
